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BACKGROUND: Lowering the diagnostic threshold for troponin is controversial because it may dispro-
portionately increase the diagnosis of myocardial infarction in patients without acute coronary syndrome.
We assessed the impact of lowering the diagnostic threshold of troponin on the incidence, management, and
outcome of patients with type 2 myocardial infarction or myocardial injury.
METHODS: Consecutive patients with elevated plasma troponin I concentrations (50 ng/L; n ¼ 2929) were
classified with type 1 (50%) myocardial infarction, type 2 myocardial infarction or myocardial injury
(48%), and type 3 to 5 myocardial infarction (2%) before and after lowering the diagnostic threshold from
200 to 50 ng/L with a sensitive assay. Event-free survival from death and recurrent myocardial infarction
was recorded at 1 year.
RESULTS: Lowering the threshold increased the diagnosis of type 2 myocardial infarction or myocardial
injury more than type 1 myocardial infarction (672 vs 257 additional patients, P < .001). Patients with
myocardial injury or type 2 myocardial infarction were at higher risk of death compared with those with
type 1 myocardial infarction (37% vs 16%; relative risk [RR], 2.31; 95% confidence interval [CI], 1.98-
2.69) but had fewer recurrent myocardial infarctions (4% vs 12%; RR, 0.35; 95% CI, 0.26-0.49). In patients
with troponin concentrations 50 to 199 ng/L, lowering the diagnostic threshold was associated with
increased healthcare resource use (P < .05) that reduced recurrent myocardial infarction and death for
patients with type 1 myocardial infarction (31% vs 20%; RR, 0.64; 95% CI, 0.41-0.99), but not type 2
myocardial infarction or myocardial injury (36% vs 33%; RR, 0.93; 95% CI, 0.75-1.15).
CONCLUSIONS: After implementation of a sensitive troponin assay, the incidence of type 2 myocardial
infarction or myocardial injury disproportionately increased and is now as frequent as type 1 myocardial
infarction. Outcomes of patients with type 2 myocardial infarction or myocardial injury are poor and do not
seem to be modifiable after reclassification despite substantial increases in healthcare resource use.
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a classification for patients with myocardial infarction based
on cause to accommodate more sensitive markers of
myocardial necrosis.1 The classification differentiates be-
tween type 1 myocardial infarction, due to thrombosis of an
atherosclerotic plaque, and type 2 myocardial infarction, dueCLINICAL SIGNIFICANCE
 Lowering the diagnostic threshold for
troponin preferentially increases the
number of patients identified with type 2
myocardial infarction or myocardial
injury.
 Patients reclassified as having type 2
myocardial infarction or myocardial
injury remained in the hospital for longer
and were more likely to undergo cardiac
investigations but, in contrast to type 1
myocardial infarction, were discharged
without additional cardiac therapies and
clinical outcomes remained poor and
unchanged.to an imbalance of myocardial
blood supply and demand that
may arise in many acute medical
and surgical conditions. The
expert consensus further defines
evidence of myocardial necrosis in
the absence of clinical evidence of
myocardial ischemia as myocar-
dial injury. Although this classifi-
cation has been used in recent
clinical trials to refine clinical
outcomes,2e4 type 2 myocardial
infarction and myocardial injury
are difficult to distinguish or di-
agnose definitively, and the fre-
quency in clinical practice and
implications of these diagnoses are
uncertain.5,6
After improvements in assay
performance, a sensitive troponin
assay was introduced into our
institution.7,8 The validation and subsequent imple-
mentation of this assay provided an opportunity to assess
the impact of lowering the diagnostic threshold on
the incidence, management, and clinical outcome of pa-
tients with type 2 myocardial infarction and myocardial
injury.MATERIALS AND METHODS
Study Population
We identified consecutive patients admitted to our
regional cardiac center (Royal Infirmary, Edinburgh,
UK), with plasma cardiac troponin I concentrations 50
ng/L irrespective of clinical presentation during the vali-
dation and implementation of a contemporary sensitive
troponin assay. We report a prespecified analysis from
a published cohort study evaluating the impact of im-
plementation of a contemporary sensitive troponin assay
on patients with suspected acute coronary syndrome.7 In
this analysis, we include all patients in whom troponin
was measured as part of routine clinical care whether or
not they presented with suspected acute coronary
syndrome.
Clinical characteristics as described previously,7
including the primary presenting symptom, referral to
specialist cardiology services, cardiac investigations,
percutaneous or surgical coronary revascularization, and
the use of medical therapies, were obtained through
“TrakCare” (InterSystems Corp, Cambridge, Mass), anelectronic patient record system used by all hospitals in
the National Health Service (NHS), Lothian, United
Kingdom. Exclusion criteria included patients admitted for
elective nonemergency procedures, patients resident
outside of Lothian, and those with incomplete hospital
records.Troponin Assay
Plasma troponin I concentrations
were measured using the
ARCHITECTSTAT assay (Abbott
Laboratories, Abbott Park, Ill).
The study was divided into 2
phases: validation and imple-
mentation. Although plasma
troponin was measured using the
reformulated sensitive assay
throughout both phases, only
concentrations above our previous
diagnostic threshold (200 ng/L)
were reported in the validation
phase, whereas concentrations
above the revised diagnostic
threshold (50 ng/L) were re-
ported during the implementation
phase.7Classification of Myocardial Infarction
Patients were classified as having a type 1 myocardial
infarction when myocardial necrosis occurred in the context
of an isolated presentation with suspected acute coronary
syndrome with chest pain or evidence of myocardial
ischemia on the electrocardiogram.1 Patients with symp-
toms and signs of myocardial ischemia on the electrocar-
diogram that were thought to be due to increased oxygen
demand or decreased supply (eg, tachyarrhythmia, hypo-
tension, or anemia) and myocardial necrosis were classified
as having a type 2 myocardial infarction. Myocardial injury
was defined as evidence of myocardial necrosis in the
absence of any clinical features of myocardial ischemia.
Myocardial infarction presenting as a sudden unexpected
cardiac death (type 3) after percutaneous coronary inter-
vention (type 4) and coronary artery bypass grafting (type
5) were also defined. Each case was reviewed and classified
independently by 2 cardiologists, and any discrepancies
were resolved by consensus through in-depth review of
source data. A total of 400 consecutive patients were
classified by 2 internal medicine physicians to determine
the generalizability of classification.Outcomes
Clinical outcomes were identified using national and local
population registries, the General Register of Scotland and
TrakCare, respectively. The primary outcomes were recur-
rent type 1 myocardial infarction and all-cause mortality at 1
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admission with chest pain or ST-segment deviation of 0.5
mm with evidence of myocardial necrosis using plasma
troponin concentrations of 50 ng/L as the diagnostic
threshold. Secondary outcomes were coronary revasculari-
zation, stroke, gastrointestinal bleeding,9 and length of stay.Statistical Analysis
Summary clinical statistics were compared by type of
myocardial infarction and between implementation and
validation phases using chi-square, Fisher exact, Student t,
and Mann-Whitney U tests where appropriate. Agreement
for the classification of myocardial infarction was estimated
using Cohen’s kappa. Cox regression models were used to
explore competing risks. Cause-specific hazard ratios were
estimated for type 1 versus type 2 myocardial infarction and
myocardial injury for time to death and time to recurrent
myocardial infarction separately with adjustment for age and
sex. Analyses were performed in SPSS (IBM Version
20.0.0; New York, NY) and R (Version 2.14.2, Vienna,
Austria).RESULTS
We identified 2929 patients with a peak plasma troponin
concentration 50 ng/L, of whom 764 met the exclusion
criteria (Online Figure 1); 1171 patients (54%) were clas-
sified with type 1 myocardial infarction, 429 patients (20%)Figure 1 Incidence rate of type 1 myocardial i
myocardial injury per 100,000 persons in Lothia
estimated as the number of events during the tota
population estimates for that age-specific stratum
incidence of type 1 than type 2 myocardial infa
100,000 persons), whereas the reverse was true fo
100,000 persons).were classified with type 2 myocardial infarction, 522 pa-
tients (24%) were classified with myocardial injury, and 43
patients (2%) were classified with type 3 to 5 myocardial
infarction. There was excellent agreement between cardiol-
ogists (k ¼ 0.92; 95% confidence interval [CI], 0.89-0.95)
and internal medicine physicians (k ¼ 0.87, 95% CI, 0.82-
0.93) for the classification of myocardial infarction.
Lowering the diagnostic threshold from 200 to 50 ng/L
identified an additional 257 patients with type 1 myocardial
infarction, 239 patients with type 2 myocardial infarction,
and 335 patients with myocardial injury: a 22%, 56%, and
64% increase, respectively (P < .001). The incidence rate
for type 1 myocardial infarction, type 2 myocardial
infarction, and myocardial injury increased with age
(Figure 1).10Clinical Characteristics
Compared with patients with type 1 myocardial infarction,
patients with type 2 myocardial infarction or myocardial
injury were older, had worse renal function, and were more
likely to be female (Table 1). Ninety-seven percent of pa-
tients with type 1 myocardial infarction had a physician
diagnosis of acute coronary syndrome, whereas patients
with type 2 myocardial infarction or myocardial injury had a
wide range of alternative clinical diagnoses (Online
Figure 2). The majority of patients with type 2 myocardial
infarction presented with chest pain and had a clearnfarction, type 2 myocardial infarction, and
n stratified by age. The incidence rate was
l 12-month period divided by the mid-year
.10 Patients aged <75 years had a higher
rction or myocardial injury (124 vs 60 per
r patients aged 75 years (750 vs 1008 per
Table 1 Baseline Characteristics of Patients with Type 1 Myocardial Infarction, Type 2 Myocardial Infarction, and Myocardial Injury
Type 1 MI (n ¼ 1171) Type 2 MI (n ¼ 429) Myocardial Injury (n ¼ 522)
Age, y 68 (14) 75 (14) 76 (13)
Male sex, (%) 709 (61%) 222 (52%) 260 (50%)
Presenting symptom, n (%)
Ischemic chest pain 1041 (89%) 217 (51%) 0 (0%)
Dyspnea 45 (4%) 80 (19%) 172 (33%)
Collapse/syncope 21 (2%) 31 (7%) 94 (18%)
Falls 18 (2%) 40 (9%) 86 (17%)
Confusion 2 (0%) 15 (4%) 23 (4%)
Palpitations 2 (0%) 4 (1%) 18 (3%)
Abdominal pain 6 (1%) 6 (1%) 12 (2%)
Cardiac arrest 14 (1%) 0 (0%) 3 (1%)
Medical history, n (%)
Ischemic heart disease 497 (45%) 191 (45%) 186 (36%)
Myocardial infarction 231 (24%) 109 (26%) 107 (21%)
Stroke 92 (8%) 48 (11%) 86 (17%)
Peripheral vascular disease 85 (8%) 29 (7%) 39 (8%)
Previous PCI 153 (15%) 17 (4%) 23 (5%)
Previous CABG 62 (6%) 30 (7%) 32 (6%)
Risk factors, n (%)
Current smoker 380 (34%) 62 (15%) 73 (14%)
Hypertension 533 (48%) 254 (59%) 303 (59%)
Hyperlipidemia 539 (49%) 177 (42%) 202 (39%)
Diabetes mellitus 185 (17%) 93 (22%) 96 (19%)
Biochemistry
Hemoglobin, mg/dL 13.3 (2.0) 12.1 (2.5) 12.0 (2.2)
Creatinine, mg/dL 1.2 (0.7) 1.5 (1.2) 1.4 (1.4)
GFR, mL/min 69 (26) 56 (30) 52 (33)
GFR <30 mL/min, % 89 (8%) 67 (16%) 125 (24%)
Cholesterol, mg/dL 185 (50) 166 (51) 171 (53)
Troponin, ng/L 2420 (270-15,230) 140 (70-660) 130 (60-390)
Change in troponin 20% 432 (86%) 41 (65%) 41 (79%)
Electrocardiography, no (%)
ST elevation 427 (38%) 40 (10%) 3 (1%)
ST depression 207 (18%) 152 (36%) 0 (0%)
T-wave inversion 125 (11%) 97 (23%) 13 (3%)
Medication on admission, no (%)
Aspirin 418 (50%) 222 (56%) 244 (54%)
Clopidogrel 100 (12%) 25 (6%) 26 (6%)
ß-blockers 257 (31%) 101 (26%) 111 (25%)
ACE inhibitors 300 (36%) 136 (34%) 158 (35%)
Statins 384 (47%) 156 (40%) 191 (42%)
Warfarin 35 (4%) 38 (10%) 52 (12%)
Proton pump inhibitors 188 (24%) 127 (33%) 135 (30%)
Values are mean (standard deviation), median (interquartile range), and counts (%).
Conversion factor to SI Units as follows: hemoglobin ¼ 10, creatinine ¼ 88.4, cholesterol ¼ 0.0259.
ACE ¼ angiotensin-converting enzyme; CABG ¼ coronary artery bypass grafting; GFR ¼ glomerular filtration rate; MI ¼ myocardial infarction;
PCI ¼ percutaneous coronary intervention; TIMI ¼ Thrombolysis in Myocardial Infarction.
496 The American Journal of Medicine, Vol 128, No 5, May 2015alternative primary diagnosis. Patients with myocardial
injury were more likely to present with dyspnea, syncope, or
confusion. The most common conditions predisposing to
type 2 myocardial infarction or myocardial injury were
tachyarrhythmia, heart failure, and respiratory disorders
(Table 1).
Peak troponin concentrations were higher in patients with
type 1 myocardial infarction at 2420 ng/L compared with
140 ng/L and 130 ng/L in patients with type 2 myocardialinfarction and myocardial injury, respectively. The majority
of patients had a 20% change in troponin concentration on
serial sampling, and this was similar across all groups. Pa-
tients with type 1 myocardial infarction were more likely to
have ST-segment elevation on the electrocardiogram,
whereas ST-segment depression and T-wave inversion were
more common in patients with type 2 myocardial infarction
and myocardial injury. The clinical characteristics of pa-
tients with type 1 and type 2 myocardial infarction did not
Shah et al Classification of Myocardial Infarction 497differ between the validation and implementation phases
(data not shown).Management During Index Admission
Compared with type 1 myocardial infarction, patients with
type 2 myocardial infarction or myocardial injury were less
likely to be referred to cardiology services, to undergo
inpatient coronary angiography and revascularization, and
to be discharged on secondary preventative therapies (P <
.01 for all) (Table 2). The median duration of hospital stay
was double in patients with type 2 myocardial infarction
(median [interquartile range]; 7 [2-17] days) and myocar-
dial injury (10 [4-23] days) compared with type 1 myocar-
dial infarction (4 [2-7] days; P < .001) (Table 2).
In patients with troponin concentration of 50 to 199 ng/L
and type 1 myocardial infarction, lowering the diagnostic
threshold increased the number of patients referred for a
specialist opinion, further investigations, and treatments forTable 2 Management and Outcomes of Patients with Type 1 Myocardi
Type 1 MI
(n ¼ 1171)
Type 2 MI
(n ¼ 429)
Management, n (%), median (IQR)
Cardiology referral 1004 (87%) 181 (43%)
Length of stay, median days (IQR) 4 (2-7) 7 (2-17)
Investigations, n (%)
Echocardiography 340 (30%) 122 (29%)
Exercise tolerance test 29 (3%) 1 (0%)
Angiography 744 (65%) 31 (7%)
Coronary revascularization, n (%)
PCI 564 (49%) 1 (0%)
CABG 56 (5%) 3 (1%)
Medications on discharge, n (%)
Aspirin 910 (90%) 166 (49%)
Clopidogrel 831 (80%) 48 (14%)
Dual antiplatelet therapy 789 (76%) 26 (7%)
ß-blockers 660 (63%) 124 (36%)
ACE inhibitors 735 (71%) 135 (39%)
Statins 884 (85%) 152 (44%)
Warfarin 35 (3%) 52 (15%)
Proton pump inhibitors 304 (29%) 135 (39%)
Outcomes, n (%)
Recurrent MI* 141 (12%) 24 (6%)
Death 187 (16%) 134 (31%)
Recurrent MI/death 280 (24%) 144 (34%)
Gastrointestinal bleeding† 20 (2%) 11 (3%)
Stroke‡ 24 (2%) 11 (3%)
Coronary revascularization§ 95 (8%) 5 (1%)
ACE ¼ angiotensin-converting enzyme; CABG ¼ coronary artery bypas
PCI ¼ percutaneous coronary intervention; RR ¼ relative risk.
*Recurrent type 1 myocardial infarction.
†Includes type IIeV bleeding as defined in the recent consensus statement
‡Defined as stroke by the attending physician.
§Coronary revascularization includes both percutaneous coronary interventio
kType 1 myocardial infarction as referent.
¶Type 2 myocardial infarction as referent.myocardial infarction (P < .01 for all) (Figure 2, Online
Table 1). Lowering the diagnostic threshold also increased
the number of patients with type 2 myocardial infarction or
myocardial injury referred to the cardiologists for further
investigation, although the proportion of patients referred
was less than for type 1 myocardial infarction and the use of
therapies for myocardial infarction was unchanged.Clinical Outcomes
Compared with patients with type 1 myocardial infarction,
patients with type 2 myocardial infarction were more likely
to die (16% vs 37%; relative risk [RR], 1.95; 95% CI, 1.61-
2.37) but less likely to have recurrent myocardial infarction
(12% vs 6%; RR, 0.46; 95% CI, 0.31-0.71) (Figure 3).
Similar risk ratios were obtained for patients with
myocardial injury with a higher proportion dead at 1 year
(16% vs 37%; RR, 2.36; 95% CI, 1.99-2.81) and fewer
recurrent myocardial infarcts (12% vs 4%; RR, 0.29; 95%al Infarction, Type 2 Myocardial Infarction, and Myocardial Injury
Myocardial Injury
(n ¼ 522)
P Value/RR
Type 1 Versus
Type 2k
P Value/RR
Type 2 Versus
Myocardial Injury¶
146 (29%) <.001 <.001
10 (4-23) <.001 <.001
117 (23%) .535 .042
0 (0%) .003 .451
19 (4%) <.001 .012
3 (1%) <.001 .632
3 (1%) <.001 .999
192 (49%) <.001 .835
38 (9%) <.001 .052
26 (6%) <.001 .547
114 (28%) <.001 .02
159 (39%) <.001 .999
190 (46%) <.001 .442
61 (15%) <.001 .965
150 (37%) .001 .508
18 (3%) .46 (0.31-0.71) .62 (0.34-1.12)
193 (37%) 1.95 (1.61-2.37) 1.19 (0.99-1.42)
203 (39%) 1.40 (1.19-1.66) 1.16 (0.98-1.38)
7 (1%) 1.50 (0.73-3.11) .52 (0.21-1.34)
22 (4%) 1.25 (0.61-2.53) 1.64 (0.81-3.35)
5 (1%) .14 (0.06-0.35) .82 (0.24-2.82)
s grafting; IQR ¼ interquartile range; MI ¼ myocardial infarction;
.11
n and coronary artery bypass grafting.
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Figure 2 Cumulative incidence of (A) recurrent myocardial infarction and (B) death in patients with type 1 myocardial infarction, type
2 myocardial infarction, and myocardial injury. Compared with patients with type 1 myocardial infarction, patients with type
2 myocardial infarction or myocardial injury were less likely to be readmitted with myocardial infarction, but were more likely to die at
1 year. In comparison with patients with type 1 myocardial infarction, more patients with type 2 myocardial infarction (16% vs 31%;
hazard ratio [HR], 1.62; 95% CI, 1.30-2.04) and myocardial injury (16% vs 37%; HR, 1.87, 95% CI, 1.52-2.30) were dead, but fewer had
recurrent myocardial infarction (12% vs 6%; HR, 0.40, 95% CI, 0.26-0.62 and 12% vs 3%; HR, 0.24; 95% CI, 0.15-0.40, respectively) at
1 year. HR presented after adjustment for age and sex with type 1 myocardial infarction as referent.
498 The American Journal of Medicine, Vol 128, No 5, May 2015CI, 0.18-0.46). Similar cause-specific hazards ratio were
seen after adjusting for age and sex for both recurrent
myocardial infarction and death (Figure 3).
In patients with troponin concentration of 50 to 199 ng/L,
lowering the diagnostic threshold was associated with a
reduction in recurrent myocardial infarction (24% vs 12%;
RR, 0.48; 95% CI, 0.27-0.88) in patients with type 1
myocardial infarction, but not in patients with type 2
myocardial infarction or myocardial injury (Figure 2,
Online Table 1). Similar reductions were observed for
death and recurrent myocardial infarction in patients with
type 1 myocardial infarction (31% vs 20%; RR, 0.64; 95%
CI, 0.41-0.99), but no change was observed in patients with
type 2 myocardial infarction (31% vs 27%; RR, 0.87; 95%
CI, 0.59-1.30) or myocardial injury (40% vs 34%; RR, 0.84,
95% CI, 0.61-1.15).DISCUSSION
The frequency and clinical implications of type 2 myocar-
dial infarction and myocardial injury in clinical practice are
uncertain. We have systematically evaluated all patients
with elevated plasma troponin concentrations admitted to a
regional cardiac center during the validation and imple-
mentation of a sensitive troponin assay and have made anumber of important and novel observations. First, type 2
myocardial infarction or myocardial injury is as common as
type 1 myocardial infarction in clinical practice irrespective
of the threshold for diagnosis. The incidence of type 2
myocardial infarction or myocardial injury increases with
age and is more common than type 1 myocardial infarction
in patients aged 75 years. Second, patients with type 2
myocardial infarction or myocardial injury have worse
clinical outcomes than patients with type 1 myocardial
infarction, with 1 in 3 patients dead at 1 year. Third,
lowering the diagnostic threshold preferentially increases
the number of patients identified with type 2 myocardial
infarction or myocardial injury. Indeed, for every additional
patient reclassified with type 1 myocardial infarction, we
identified 3 patients with type 2 myocardial infarction or
myocardial injury. Finally, patients reclassified as type 2
myocardial infarction or myocardial injury remained in the
hospital longer and underwent more cardiac investigations
but, in contrast to type 1 myocardial infarction, were dis-
charged without additional cardiac therapies and clinical
outcomes remained poor and unchanged.
The Universal Definition makes a distinction between
type 2 myocardial infarction and causes of elevations in
plasma troponin resulting in myocardial injury, such as renal
failure, heart failure,12 sepsis,13,14 and myopericarditis,15
Figure 3 Change in the investigation, management, and clinical outcomes of patients with type 1
myocardial infarction, type 2 myocardial infarction, and myocardial injury after implementation of a
sensitive troponin assay. In patients with troponin concentrations of 50 to 199 ng/L and type 1
myocardial infarction, lowering the diagnostic threshold increased referrals for a specialist opinion,
further investigation, and treatments for myocardial infarction (P < .01 for all). For patients with type
2 myocardial infarction and myocardial injury, similar patterns were seen, although the absolute
magnitude was smaller. In patients with type 1 myocardial infarction, lowering the diagnostic
threshold was associated with a significant reduction in recurrent myocardial infarction (absolute risk
reduction, 12%; 95% CI, 3-23), whereas outcomes in patients with type 2 myocardial infarction and
myocardial injury remained unchanged. DAPT ¼ dual antiplatelet therapy; MI ¼ myocardial
infarction; PCI ¼ percutaneous coronary intervention. *P < .05. ** P < .01. ***P < .001.
Shah et al Classification of Myocardial Infarction 499and defines myocardial infarction, regardless of pathobi-
ology, as evidence of myocardial necrosis in the presence of
clinical symptoms and signs of myocardial ischemia.16,17
However, it is clinically challenging to distinguish be-
tween patients with type 2 myocardial infarction and
myocardial injury because there remains considerable
overlap between these 2 clinical entities.5,6 The consensus
document does not provide specific criteria on how to
differentiate between these entities in clinical practice, and
our analysis represents one of the first attempts to do so in
consecutive hospitalized patients. Thus, our frequency data
may differ from those of others who may have applied a
different criteria to define type 1 myocardial infarction and
may or may not have had a category for myocardial injury.
Accordingly, the frequency of type 2 myocardial infarction
in our study of 20% (429/2165) was lower than in the only
previous reports in which the frequency was 30% (64/701
patients)18 and 26% (144/553 patients)19 in unselected
hospitalized patients with elevated troponin concentrations.
Our analysis is novel in that we distinguish between patients
with type 2 myocardial infarction and myocardial injury,
and differences in classification may explain the lower rates
of type 2 myocardial infarction in our cohort. Perhaps it is
not surprising that type 2 myocardial infarction has beenreported to be less frequent (2%-5%) in highly selected
populations with myocardial infarction from randomized
controlled trials or registries of patients admitted to cardiac
units.4,11,20 Our patients were widely distributed across
medical and surgical specialties, and it is likely that selec-
tion bias has underestimated the true prevalence of type 2
myocardial infarction in these studies.
One of the main strengths of our study is that we iden-
tified a group of patients admitted during the validation
period in whom plasma troponin concentrations of 50 to 199
ng/L were reported as normal. This allowed us to assess the
impact of implementation of a sensitive troponin assay on
the management and clinical outcome of these patients.
Lowering the diagnostic threshold for myocardial infarction
increased the use of appropriate investigations and treat-
ments in patients with type 1 myocardial infarction. This
was associated with a reduction in recurrent myocardial
infarction and death consistent with our previous report.7 In
contrast, there was no improvement in the clinical outcome
of patients with type 2 myocardial infarction or myocardial
injury despite increased referral to cardiology services and
subsequent additional invasive and noninvasive in-
vestigations. Approximately one third of patients with type
2 myocardial infarction were dead at 1 year. These findings
500 The American Journal of Medicine, Vol 128, No 5, May 2015are consistent with those of Saaby et al,21 who observed
mortality rates that were 2-fold higher in patients with type 2
myocardial infarction compared with type 1 myocardial
infarction. Of note, despite more patients being identified as
having type 2 myocardial infarction after lowering the
diagnostic threshold, the majority of these patients did not
receive additional therapies for coronary heart disease. This
may represent a missed opportunity to improve outcomes,
and further prospective studies are required to define the
optimal management of patients with type 2 myocardial
infarction.
The increased frequency of type 2 myocardial infarction
or myocardial injury is likely to be even more marked with
the development of the next-generation high-sensitivity
troponin assays that will permit further lowering of the
diagnostic threshold for myocardial infarction.22-24 These
assays are likely to identify an even greater and more
disproportionate number of patients with myocardial injury
or type 2 myocardial infarction. However, this must not
detract from the substantial benefits that high-sensitivity
assays will confer for diagnosing patients with type 1
myocardial infarction.25,26 This underlines the need to pro-
vide additional guidance on how to distinguish between
myocardial infarction and myocardial injury.27
We believe there remains scope for clarification of the
diagnostic criteria for type 2 myocardial infarction and
that this is necessary to help clinicians adopt the proposed
classification. Acute myocardial injury should be the
initial diagnosis in all patients with troponin elevations
due to supplyedemand imbalance, including those with
chest pain or evidence of myocardial ischemia. This would
be in keeping with many other organ systems, such as
acute liver or kidney injury, where similar elevations in
tissue enzymes or biomarkers confer major prognostic
value but are not disease specific. In our opinion, type 2
myocardial infarction classification should be used
exclusively in patients in whom coronary artery disease
has contributed to myocardial injury and there may be
opportunities to improve outcomes through medical ther-
apy or coronary revascularization. Selection of patients for
further investigation will depend on the mechanism of
myocardial injury and the patient’s probability of having
coronary artery disease.5Study Limitations
Despite our careful attempts to classify patients, we were
reliant on investigations performed by attending clinicians.
Although agreement between our adjudicating cardiologists
and internal medicine physicians was excellent, we accept
that a small proportion of patients with type 2 myocardial
infarction or myocardial injury may have been misclassified.
Furthermore, we were unable to differentiate between acute
and chronic myocardial injury in many patients because
serial samples were requested at the discretion of the clinical
team and were not routinely obtained in patients without
suspected acute coronary syndrome.CONCLUSIONS
We have demonstrated that type 2 myocardial infarction and
myocardial injury are now as common as type 1 myocardial
infarction in clinical practice. With the use of a sensitive
troponin assay, we identified 3 patients with type 2
myocardial infarction or myocardial injury for every patient
reclassified with type 1 myocardial infarction. Although this
was associated with better treatment and outcomes in pa-
tients with type 1 myocardial infarction, patients with type 2
myocardial infarction or myocardial injury underwent more
investigations and used additional cardiac services without
altering their poor clinical outcome.References
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Online Figure 1 CONSORT diagram of study population stratified by infarct type and study phase.
Consecutive patients with plasma troponin I concentrations 50 ng/L were identified irrespective of clinical
presentation during the validation (February 1, 2008, to July 31, 2008) and implementation (February 1,
2009, to July 31, 2009) of a contemporary sensitive troponin I assay (n ¼ 2929). Exclusion criteria were
limited to patients admitted for elective nonemergency procedures, patients who were resident outside of
Lothian, and patients with incomplete hospital records. The remaining 2165 patients were classified with
type 1 to 5 myocardial infarction or myocardial injury. Although plasma troponin was measured using a
reformulated sensitive assay throughout both phases, only concentrations above a diagnostic threshold of 200
ng/L were reported in the validation phase, whereas concentrations above a revised diagnostic threshold of
50 ng/mL were reported during the implementation phase. MI ¼ myocardial infarction.
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Online Figure 2 Primary diagnosis of patients with type 2 myocardial infarction and myocardial injury. Patients
classified with (A) type 2 myocardial infarction or (B) myocardial injury were a heterogeneous group presenting to
a wide range of medical and surgical specialties. Most patients with type 2 myocardial infarction had a cardiac or
respiratory diagnosis, with heart failure and arrhythmias the most common cause of elevated troponin
concentrations.
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Online Table 1 Clinical Investigations, Management, and Outcomes in Patients with Troponin Concentration Between 50 and 199 ng/L in Patients with Type 1 Myocardial Infarction,
Type 2 Myocardial Infarction, and Myocardial Injury
Validation
(n ¼ 136)
Implementation
(n ¼ 121)
P Value/Relative
Riskk (95% CI)
Validation
(n ¼ 125)
Implementation
(n ¼ 114)
P Value/Relative
Riskk (95% CI)
Validation
(n ¼ 237)
Implementation
(n ¼ 98)
P Value/Relative
Riskk (95% CI)
Cardiology referral 67 (50%) 96 (83%) <.001 31 (26%) 53 (48%) .001 40 (18%) 27 (28%) .043
Investigations, n (%)
Echocardiography 6 (4%) 16 (13%) .014 19 (15%) 31 (27%) .023 28 (12%) 23 (24%) .007
Exercise tolerance test 6 (4%) 3 (2%) >.99 1 (1%) 0 (0%) .999 0 (0%) 0 (0%) e
Angiography 36 (27%) 60 (52%) <.001 3 (3%) 10 (9%) .032 2 (1%) 5 (5%) .025
Coronary revascularization, n (%)
PCI 19 (14%) 34 (30%) .005 1 (1%) 0 (0%) .999 0 (0%) 0 (0%) e
CABG 7 (5%) 3 (3%) 1.00 1 (1%) 1 (1%) .999 0 (0%) 0 (0%) .376
Medications on discharge, n (%)
Aspirin 91 (73%) 95 (85%) .038 52 (47%) 53 (54%) .366 92 (47%) 35 (43%) .595
Clopidogrel 53 (43%) 75 (63%) .002 10 (9%) 11 (11%) .628 8 (4%) 7 (9%) .124
Dual antiplatelet therapy 47 (38%) 65 (58%) .003 6 (6%) 5 (5%) .896 4 (2%) 3 (4%) .418
ß-blockers 68 (55%) 67 (60%) .511 37 (34%) 37 (37%) .573 50 (25%) 23 (28%) .572
ACE-inhibitors 64 (52%) 76 (68%) .017 39 (36%) 45 (46%) .141 70 (35%) 38 (47%) .072
Statins 82 (57%) 85 (76%) .150 42 (38%) 49 (50%) .100 95 (48%) 31 (38%) .130
Warfarin 9 (5%) 7 (6%) .770 18 (17%) 17 (17%) .923 26 (13%) 15 (19%) .263
Proton pump inhibitors 23 (23%) 51 (46%) .001 41 (38%) 33 (33%) .488 60 (31%) 30 (37%) .299
12-mo outcomes, n (%)
Recurrent MI* 33 (24%) 14 (12%) .48 (0.27-0.88) 10 (8%) 8 (7%) .88 (0.36-2.14) 13 (6%) 3 (3%) .56 (0.19-1.92)
Death 19 (14%) 12 (10%) .71 (0.36-1.40) 34 (27%) 29 (25%) .94 (0.61-1.43) 86 (36%) 33 (34%) .93 (0.67-1.28)
Recurrent MI/death 42 (31%) 24 (20%) .64 (0.41-0.99) 39 (31%) 31 (27%) .87 (0.59-1.30) 95 (40%) 33 (34%) .84 (0.61-1.15)
Gastrointestinal bleeding† 2 (2%) 3 (3%) 1.67 (0.29-9.92) 2 (2%) 2 (2%) 1.10 (0.16-7.66) 3 (1%) 4 (4%) 3.22 (0.73-14.14)
Stroke‡ 2 (2%) 1 (1%) .56 (0.05-6.12) 2 (2%) 3 (3%) 1.10 (0.23-5.32) 13 (6%) 3 (3%) .56 (0.16-1.92)
Coronary revascularization§ 17 (13%) 15 (12%) .99 (0.51-1.90) 1 (1%) 1 (1%) 1.10 (0.07-17.32) 4 (2%) 0 (0%) e
Values are mean (standard deviation), median (interquartile range), and counts (%).
ACE ¼ angiotensin-converting enzyme; CABG ¼ coronary artery bypass grafting; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
*Recurrent type 1 myocardial infarction.
†Includes type 2eV bleeding as defined in the recent consensus statement.11
‡Defined as stroke by the attending physician.
§Coronary revascularization includes both percutaneous coronary intervention and coronary artery bypass grafting.
kRRs comparing implementation phase with validation phase as the reference group.
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